Leukaemia Trial, Recruiting NCT02677064 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT02677064
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with or have had a return of acute leukemia, including those whose leukemia did not respond to initial treatment attempts.
  • People diagnosed with certain blood and bone marrow conditions — myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), or an overlap of both — who meet at least one of the following: low levels of two or more types of blood cells (low red blood cells, platelets below 100,000, or infection-fighting cells below 1,000); more than 5% abnormal cells (blasts) in the bone marrow or any abnormal cells in the blood; disease that has gotten worse or has not responded to certain standard treatments or a clinical trial; a disease severity rating of "Intermediate-1" or higher on standard scoring systems used by doctors (confirm with trial site).
  • People with a bone marrow scarring condition called myelofibrosis who have low-risk disease but also have anemia requiring blood transfusions, certain abnormal cell levels in the blood, or certain chromosomal changes — or anyone with myelofibrosis rated "Intermediate-1" or higher on a standard severity scale (confirm with trial site).
  • People whose acute leukemia or MDS/MPN has returned after having received a bone marrow or stem cell transplant from a donor.
  • People aged 18 to 80 years old.

Who may not be able to join:

  • People whose diagnosis is polycythemia vera (a condition where the body makes too many red blood cells) or essential thrombocytosis (a condition where the body makes too many platelets).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 February 2016
Est. completion
1 February 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

number of patients who proceed to transplant

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov